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ABSTRACT: A quinolizidine-type alkaloid aloperine was found to
inhibit HIV-1 infection by blocking HIV-1 entry. Aloperine inhibited
HIV-1 envelope-mediated cell−cell fusion at low micromolar con-
centrations. To further improve the antiviral potency, more than
30 aloperine derivatives with a variety of N12-substitutions were
synthesized. Among them, 12d with an N-(1-butyl)-4-trifluorome-
thoxy-benzamide side chain showed the most potent anti-HIV-1
activity with EC50 at 0.69 μM. Aloperine derivatives inhibited both X4 and R5 HIV-1 Env-mediated cell−cell fusions. In addition,
both BMS-806, a compound representing a class of HIV-1 gp120-targeting small molecules in clinical trials, and resistant and
sensitive HIV-1 Env-mediated cell−cell fusions were equally sensitive to aloperine derivatives. These results suggest that
aloperine and its derivatives are a new class of anti-HIV-1 entry inhibitors.
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HIV-1 infection and AIDS have afflicted millions of people
worldwide.1,2 Although the antiretroviral therapy (ART) for
HIV/AIDS has been successful in controlling the viral repli-
cation in infected individuals,3,4 the current therapy has failed
to achieve a full cure due to the difficulty of eradicating latent
viral reservoirs in patients.5−8 Thus, long-term drug treatment for
HIV patients is expected. Hence, drugs with novel mechanisms
of action may mitigate side effects or drug resistance encountered
during long-term ART. ART was characterized by a combination
of drugs that target viral or cellular proteins essential for virus
replication. HIV-1 entry is a complex multistep process that
involves the initial binding of viral envelope protein (gp120) to
cellular receptors such as CD4 and CCR5 or CXCR4, followed
by conformational changes in viral envelope glycoproteins to
initiate the membrane fusion between HIV-1 and its target cells.
There are two FDA-approved anti-HIV entry drugs: Fuzeon
(enfuvirtide) and Selzentry (maraviroc). Fuzeon and Selzentry
inhibit HIV-1 by targeting HIV gp41 and blocking coreceptor
CCR5, respectively.9,10 However, there is no FDA approved
antiretroviral that targets HIV-1 gp120. The most advanced viral
envelope glycoproteins targeting small molecules in develop-
ment are a class of piperazine derivatives, such as BMS-378806
(BMS-806) and BMS-626529.11 In an effort to identify novel
HIV-1 entry inhibitors, we have identified a class of betulinic acid
derivatives that blocks the HIV entry through binding to the
gp120 at the third variable loop (V3 loop).12−14 In this study, we
describe aloperine derivatives, a class of tetracyclic quinolizidine
alkaloids, as new HIV entry inhibitors.
Aloperine was first isolated from the seeds and leaves of
Sophora alopecuroides L.15,16 The core of this alkaloid is a
unique bridged tetracyclic ring system composed of an octa-
hydroquinoline ring partially overlapped with a quinolizidine
ring. We have recently studied the potential antiviral activity of
a series of quinolizidine alkaloids and discovered that aloperine
can inhibit both the HIV-1 (Table 1) and influenza A virus
(IAV).17 It is possible that aloperine targets a common cellular
factor essential for replication of both viruses. However, our
recent study indicated the anti-IAV activity of aloperine was
linked to the nucleoprotein (NP) of IAV.17 The objective of this
study is to determine the anti-HIV-1 activity of aloperine and its
derivatives. The structure−activity relationships and likely
mechanism of action of this class of compounds are discussed.
The general structure of the compounds synthesized in this
study is aloperine-(CH2)n-NH-R, where (CH2)n is a linker of
varied length and R is either a hydrogen or an aromatic group.
To synthesize N-substituted derivatives, aloperine was coupled
with a Boc protected amino alkyl bromide in the presence of
potassium carbonate under microwave heat, followed by
deprotection of amine group to form N-(ω-aminoalkanyl)-
aloperine (5a−5e). Compounds 6a−6e, 7a−7c, 8a−8c, 9a, 9b,
10a, 10b, 11a, 11b, and 12a−12f were obtained by further
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acylation of 5a−5e with aromatic carboxylic acid reagents,
while 13a−13c were obtained by treating 5c or 5d with alkyl
bromide in the presence of potassium carbonate under
microwave heat (Scheme 1).
Anti-HIV Activity. To evaluate the anti-HIV activity of
aloperine and the synthesized compounds, HIV-1 NL4-3
Nanoluc-sec virus infection of MT4 cells was performed in
the presence of various concentrations of compounds. HIV-1
NL4-3 Nanoluc-sec virus is a reporter virus containing a
secNluc insertion as a reporter gene (Promega Cat.# N1021).
The viral replication thus can be monitored by measuring the
luciferase activity using Promega Nano-Glo Luciferase Assay
System (Supporting Information). Under this assay condition,
aloperine (1) inhibited the virus with an EC50 of 1.75 μM.
Our initial attempts of optimizing aloperine for higher
potency included adding a small substituent at the N12 position
and reducing the double bond on its quinolizidine scaffold.
However, these structural modifications failed to yield active
compounds against HIV-1, despite some of them, such as
compounds 2−4, showed more potent anti-IAV activity than
aloperine.17 Due to the likely negative impact of N12
substitution on the anti-HIV activity, a linker −(CH2)n− was
introduced at N12 to conjugate aloperine with a terminal
aromatic moiety. The length of the linker varied between two
to six carbons. The anti-HIV activity of aloperine derivatives is
summarized in Table 1.
Among the synthesized compounds, those with various
lengths of amine linkers but without a cyclical terminal group
(5a−5e) were less active than aloperine. However, 5c and 5d
with n = 4 and 5, respectively, partially retained their anti-HIV
activity. The length of the linkers was critical for the anti-HIV
activity of aloperine derivatives with terminal aromatic
substitutions. For example, for compounds 6a−6e with the
same terminal trifluoromethoxy substituted benzamide group,
the optimal linker length for anti-HIV activity was n = 4 or 5 in
compounds 6d and 6c. These two compounds showed
improved anti-HIV activity with EC50 of 1.1 and 0.98 μM,
respectively. This structure−activity relationship was also
observed in 7a−7d and 8a−8c series.
There is a common structural motif shared among three
compounds, 6c, 6d, and 7c, which exhibit relatively high anti-
HIV potency with EC50 ranging from 0.75 to 1.12 μM. All of
the three compounds have a para-trifluoromethoxy substituent
(−OCF3) on the terminal aromatic ring. The importance of the
OCF3 substitution at the para position was confirmed by a
decrease and a total loss of anti-HIV-1 activity in the meta-
(11a) and ortho-substituted analogue (11b), respectively.
Derivatives with same linker length (n = 4) but with various
para-substitutions on the benzamide terminal moiety were
synthesized and compared for their anti-HIV-1 activity.
A trifluoromethyl group on the benzamide ring appeared to
Table 1. Anti-HIV Activity of N12 Modified Aloperine
Derivativesa
aCompounds were evaluated by using a multicycle viral replication assay
using HIV-1 NL4-3 Nanoluc-sec virus (Supporting Information). bEC50 is
the concentration that inhibited HIV-1 replication by 50%; presented as an
average of three experiments ± standard deviation (SD). cN/A: inactive
(>10 μM). dCC50 is concentration that reduced cell viability by 50%.
Scheme 1. Synthesis of Aloperine Derivatives 5a−13ca
aReagents and conditions: (a) Br(CH2)nNHBoc, K2CO3, MeCN, 110
°C, MW, 1 h; (b) TFA, DCM, rt, 20 min; (c) carboxylic acid, EDC,
TEA, THF, rt, overnight; (d) alkyl bromide, K2CO3, MeCN, 110 °C,
MW, 1 h.
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be preferred for anti-HIV activity. The compound with CF3
substitution (12d) showed the best anti-HIV activity with an
EC50 of 0.69 μM, while 6c with OCF3 was also relatively potent
with EC50 at 1.12 μM. Compounds 12c, 12e, and 12f with
CH3, OH, and OMe on the benzamide moiety were only
weakly active with EC50 at 4.57−8.13 μM. Compounds without
any substitution (12a) or with p-fluoride (12b) at the benzene
ring did not show any anti-HIV activity.
Unlike other amide derivatives, compounds 13a−13c are
amine derivatives. Two unsubstituted benzyl amines (13a and
13b) exhibited improved potency over aloperine with EC50
lower than 1 μM. Surprisingly, the p-OCF3 substituted analog
(13c) was less active against HIV-1. However, the three amine
derivatives appeared to be more toxic to MT4 cells than other
aloperine derivatives with CC50 ranging from 6.20 to 28.56 μM.
The trifluoromethoxy-substituted phenylacrylic derivatives
(9a and 9b) were also more toxic than other compounds as well.
Inhibition of a Panel of Pseudotype Viruses with HIV-1
Env from Various Subtypes. HIV-1 envelope glycoproteins
are highly diversified and may have differential sensitivity to
HIV-1 entry inhibitors. Therefore, one of the most potent
aloperine derivatives, 7c, was tested against a panel of pseudo-
type viruses containing HIV-1 Env from strains of various HIV-1
subtypes. These viruses were originally constructed as reference
strains for HIV-1 vaccine evaluation.18 The result indicated that
these viruses were inhibited by 7c with EC50 ranging from
0.9 to 4.3 μM (Table 2). Considering the high diversity of
HIV-1 Envs, 7c possesses relatively broad anti-HIV-1 activity
against the tested viruses across various subtypes, such as B, C,
and G, and some circulating recombinant forms (CRF).
Aloperine Inhibited HIV-1 Env-Mediated Cell−Cell Fusion.
A time of addition study of aloperine indicated that the
sensitive phase of HIV-1 life cycle to the compound is at an
early phase of HIV-1 infection (data not shown). HIV-1 NL4-3
infection of MT4 cells was not sensitive to aloperine when the
compound was added 2 h post infection. Therefore, HIV-1
entry is a likely target for aloperine. We have previously studied
an entry inhibitor A43D using an HIV-1 Env-mediated cell−cell
fusion system.14,19−21 This model uses HIV Env-expression
COS cells to fuse with TZM-bl cells, which expresses luciferase
upon fusion (Supporting Information).
As expected, the entry inhibitor A43D inhibited both YU2 and
NL4-3 Env-mediated membrane fusion (Figure 1). Aloperine
also inhibited both NL4-3 and YU2 envelope-mediated
membrane fusion with EC50 at 1.2 and 1.6 μM, respectively.
The aloperine derivative 7c was also tested against the NL4-3-
Env-mediated cell−cell fusion, and it was slightly more potent
than aloperine. HIV-1 NL4-3 uses CXCR4 and YU2 uses
CCR5 as coreceptors for entry. These results suggest that
aloperine can inhibit the entry of both X4 and R5 viruses. A43D
is slightly more potent against HIV NL4-3 than the YU2 strain,
while aloperine exhibited similar potency toward the HIV-1
Env-mediated cell−cell fusion of both viruses.
Aloperine Inhibited BMS-806 Resistant Virus Env-Medi-
ated Cell−Cell Fusion. BMS-806 was used in comparison with
aloperine in this study to determine their activity against BMS-
resistant viruses. BMS-806 is the prototype analogue of the
HIV-1 entry inhibitor BMS-626529 under clinical trials.23−25
Aloperine was tested against BMS-806 resistant virus YU2-
T198P Env-mediated cell−cell fusion. The BMS-806 resistant
virus YU2-T198P is a YU2 mutant with a T198P mutation in
the bridging sheet of gp120 that played an important role in the
function of gp120.12 Bridging sheet is also a critical determinant
for BMS-806 sensitivity.26−29 BMS-806 potently inhibited
YU2 Env-mediated cell−cell fusion with an EC50 of 0.1 μM
(Figure 2). In contrast, YU2-T198P Env-mediated cell−cell
fusion was completely resistant to BMS-806 at a concentration
as high as 5 μM. However, YU2-T198P was slightly more
sensitive to aloperine when compared to YU2.
BMS-806 and aloperine were also tested for their activity
against the cell−cell fusion mediated by HIV-1 8x Env.30 HIV-1
8x is a CD4-independent virus that may be resistant to
BMS-806 since the CD4 binding site on HIV-1 gp120 was
implicated as a key determinant for BMS-806 sensitivity.27
Indeed, the HIV-1 8x Env-mediated cell−cell fusion was not
sensitive to BMS-806 at concentrations up to 5 μM (Figure 2).
However, the HIV-1 8x Env-mediated cell−cell fusion
remained sensitive to aloperine. In addition, an aloperine deri-
vative 7c did not affect HIV-1 IIIB gp120/CD4-IgG2 binding
(Figure S1, Supporting Information). These results suggest that
BMS-806-resistant Env-mediated cell−cell fusion, such as that
Table 2. Anti-HIV Activity of Compound 7c against
Pseudotype Virusesa
virus subtypes (clades) EC50 (μM)
CE1176 C 2.2 ± 0.64
CNE55 CRF01_AE 4.3 ± 1.1
CE0217 C 1.4 ± 0.43
X1632 G 2.5 ± 0.55
BJOX2000 CRF07_BC 2.8 ± 0.96
25710 C 2.1 ± 0.81
TRO11 B 1.6 ± 0.45
CH119 CRF07_BC 0.9 ± 0.36
aThe antiviral activity of compound 7c was determined using a TZM-bl
assay as previously described.14 Compound 7c was not toxic to TZM-bl
cells at the highest tested concentration (20 μM). EC50 is the
concentration that inhibited the pseudotype virus infection of TZM-bl
cells by 50%.18 The data in the table represent mean ± SD of three
independent experiments.
Figure 1. Inhibition of HIV-1 Env-mediated cell−cell fusion by
aloperine and its derivative 7c. The cell fusion was quantified by a
Promega luciferase reagent kit as previously described.21,22 HIV-1 Env
expressing COS cells were fused with TZM-bl cells for 24 h; 100%
fusion is defined as fusion in the absence of inhibitors. NL4-3/A43D
(and the like) in the figure represents the dose-dependent curve of the
effects of A43D on NL4-3 Env-mediated cell−cell fusion. Each data
point was derived from three independent experiments.
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mediated by YU2-T198P and 8x, may be inhibited by aloperine.
Although HIV-1 8x Env was resistant to BMS-806 in this
study, it should be noted that the evolution of BMS-806 into
the active moiety of the clinical candidate (BMS-626529)
resulted in a compound that was active against the HIV 8x
envelope.31
There are more than 30 FDA approved formulations for anti-
HIV therapy. Only two of the drugs, enfuvirtide and maraviroc,
are HIV-1 entry inhibitors.9,10,32 Maraviroc is a coreceptor
CCR5 inhibitor that potently blocks the infection of R5 HIV
strains but is ineffective against X4 HIV strains. Enfuvirtide is a
polypeptide drug that targets HIV-1 gp41 and arrests HIV-1
envelope-mediated membrane fusion. In this study, the lead
compound aloperine is an HIV-1 entry inhibitor exhibiting
several unique pharmacological properties. First, compared to
enfuvirtide (MW = 4492), aloperine is a much smaller molecule
(MW = 232). Second, aloperine inhibits entry of both R5 and
X4 viruses while maraviroc only inhibits R5 viruses. Third,
aloperine inhibits entry with a mechanism different from that of
maraviroc.
In addition to the FDA approved HIV-1 entry inhibitors,
BMS-663068 (a prodrug of BMS-626529) is one of the most
promising HIV-1 entry inhibitors undergoing clinical trials.33
BMS-626529 is a BMS-806 analogue targeting the CD4 binding
site on HIV-1 gp120. HIV-1 can become essentially insensitive
to BMS-806 with a single amino acid mutation near the
bridging sheet of HIV-1 gp120 as shown in Figure 2. It is
interesting that HIV-1 Env-mediated cell−cell fusion of both
the BMS-806-resistant and -sensitive strains is equally sensitive
to aloperine. In summary, aloperine and analogues represent a
new class of anti-HIV-1 entry inhibitors with chemical
structures distinct from other HIV-1 entry inhibitors.
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